Skip to main content

Table 1 The mutational landscape of PTCL

From: Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma

Mutational gene Most frequent subtype frequency Frequent mutation in tumour type
TET2 [9, 10, 14, 116] AITL, PTCL-NOS 42-89%,
28-48, 5%
MPN (~13%),
(CMML) (~50%),
MDS (25%),
AML(~23%) [154]
DNMT3A [10, 14] AITL, PTCL-NOS 25-33%, 27% AMLs (20–30%),
MDS (10–15%) [155]
IDH2 AITL [11] PTCL-NOS 20-45%,
7.5%156
AML(8–19%) [157]
MDS (~5%) [158]
KMT2D/MLL2
[12, 58, 93]
All PTCL, AITL,
PTCL-NOS
42%, 25%, 36% DLBCL (35–85%) [159]
FL (89%) [160]
KMT2C,
SETD1B
PTCL, NOS [93, 156] 8.2%, 5.2% Breast [161] cancer 8%MLL2+MLL3(16-20%)
medulloblastoma [162, 163]
SETD2 EATL
MEITL
32%, [83]
21/23 (91%) [84]
Renal cell carcinoma
(13-30%) [164]
  1. TET: ten eleven translocation protein, 2HG:2-hydroxyglutarate, IDH2: isocitrate dehydrogenase2, 5hmC: 5-hydroxymethylcytosine, EZH2: enhancer of zeste 2, MDS: myelodysplastic syndromes, AML: acute myeloid leukaemia